AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7998047
Drug: lisinopril 10‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril 10‐40 mg
Trial: 7998047
Drug: nifedipine 20‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 20‐80 mg
Trial: 30275095
Drug: Benznidazole (BNZ)
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole (BNZ) administered to healthy male volunteers, specific dosage not mentioned.
Trial: 21036512
Drug: Opioid maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid maintenance medications
Trial: 21036512
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment programs
Trial: 17006925
Drug: Uracil-tegafur (UFT)
RxNorm normalized name: tegafur / uracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uracil-tegafur (UFT) 300 mg/day for 1 year after surgery (n = 79)
Trial: 14583715
Drug: 1.5 mL
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL 4% atomized lidocaine
Trial: 14583715
Drug: 1.5 mL
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL 4% atomized cocaine
Trial: 14583715
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL 2% lidocaine gel
Trial: 10768306
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) treatment
Trial: 1298089
Drug: Fansimef (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fansimef (125 mg mefloquine + 250 mg sulfadoxine + 12.5 mg pyrimethamine)
Trial: 1298089
Drug: Lariam (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lariam (125 mg mefloquine)
Trial: 1298089
Drug: Fansidar (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fansidar (500 mg sulfadoxine + 25 mg pyrimethamine)
Trial: 1298089
Drug: Chloroquine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (300 mg)
Trial: 25090110
Drug: HVTN 503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine
Trial: 22733022
Drug: Bolus flavopiridol
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus flavopiridol (50 mg/m²/day, Arm A)
Trial: 22733022
Drug: Hybrid flavopiridol
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid flavopiridol (30 mg/m² over 30 min followed by 40 mg/m² over 4 h, Arm B)
Trial: 17588490
Drug: 12-step-based drug
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-step-based drug treatment program (Treatment group)
Trial: 16320747
Drug: Electroacupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture and ultrashort‐wave treatment from the acute stage (Group A)
Trial: 16320747
Drug: Ultrashort‐wave treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrashort‐wave treatment at the acute stage and ultrashort‐wave plus electroacupuncture at the resting stage (Group B)
Trial: 11782652
Drug: High-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat diet (2.5 g x kg(‐1) x d(‐1) CHO, 4.3 g x kg(‐1) x d(‐1) fat; FAT-adapt)
Trial: 11782652
Drug: High-carbohydrate diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate diet (9.3 g x kg(‐1) x d(‐1) CHO, 1.1 g x kg(‐1) x d(‐1) fat; HCHO)
Trial: 7853690
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) at 20 mg/kg
Trial: 7853690
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) at 40 mg/kg
Trial: 66871
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B immune serum globulin (antibody titer 1:355,000)
Trial: 6101354
Drug: Post-treatment equilin
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment equilin levels in group 1
Trial: 6101354
Drug: Post-treatment equilin
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment equilin levels in group 2
Trial: 30964969
Drug: Oral‐B Genius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B Genius 8000 with FlossAction brush head (OBG)
Trial: 30964969
Drug: Oral‐B Genius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B Genius 8000 (OBG)
Trial: 27129571
Drug: Preoperative ultrasound-guided
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative ultrasound-guided bilateral TAP block with 0.5 mL/kg of 0.25% bupivacaine
Trial: 27345639
Drug: Deferred radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred radiotherapy (same dose given within 35 days of PTM diagnosis)
Trial: 11222470
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg TID (n=20)
Trial: 9893547
Drug: Pethidine 5
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 5 mg.ml‐1 with adrenaline 5 micrograms.ml‐1 (adrenaline group)
Trial: 9893547
Drug: Pethidine 5
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 5 mg.ml‐1 without adrenaline (plain group)
Trial: 7986965
Drug: Alosetron 1
RxNorm normalized name: alosetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 1 mg b.d. for 6 days
Trial: 2735519
Drug: Turbuhaler (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler (0.5 mg terbutaline sulphate)
Trial: 2735519
Drug: Metered Dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered Dose Inhaler (MDI) (0.5 mg terbutaline sulphate)
Trial: 31200823
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (icotinib plus pemetrexed and carboplatin)
Trial: 27865015
Drug: Any cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any cannabis use during treatment
Trial: 23644079
Drug: Azathioprine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2.5 mg ∙ kg(‐1) ∙ day(‐1))
Trial: 23644079
Drug: Conventional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional management (immunosuppressant therapy only if corticosteroid dependency, chronic active disease, poor response to corticosteroids, or severe perianal disease)
Trial: 21078826
Drug: Intermittent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent chemotherapy with levo‐leucovorin + 5‐fluorouracil (5‐FU) + irinotecan (CPT‐11), administered every 2 weeks for 2 months on and 2 months off (arm A)
Trial: 21078826
Drug: Continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chemotherapy with levo‐leucovorin + 5‐fluorouracil (5‐FU) + irinotecan (CPT‐11), administered continuously (arm B)
Trial: 21078826
Drug: Intermittent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent chemotherapy (arm A)
Trial: 21078826
Drug: Continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chemotherapy (arm B)
Trial: 21078826
Drug: Second-line oxaliplatin-based
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Second-line oxaliplatin-based treatment
Trial: 15001789
Drug: Daily additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily additional sensorimotor stimulation of the arm for 6 weeks
Trial: 10744088
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg alosetron orally twice daily for 12 weeks
Trial: 10744088
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally twice daily for 12 weeks
Trial: 8759064
Drug: Quinapril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (40 mg daily)
Trial: 30995176
Drug: Idelalisib (IDELA)
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib (IDELA) 150 mg twice daily plus rituximab
Trial: 27889290
Drug: Topical broccoli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical broccoli sprout extract (BSE) (500 nmol of sulforaphane/mL)
Trial: 17638004
Drug: Patching plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patching plus oral CDP‐choline (800 or 1,200 mg based on body weight) for 30 days
Trial: 7574020
Drug: 6% hetastarch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hetastarch plus 1 L lactated Ringer's solution (n = 20)
Trial: 7574020
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (n = 20)
Trial: 1662879
Drug: Oral temafloxacin
RxNorm normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral temafloxacin (600 mg b.i.d.)
Trial: 1662879
Drug: Oral cefadroxil
RxNorm normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cefadroxil (500 mg b.i.d.)
Trial: 31706460
Drug: Abriendo Caminos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abriendo Caminos Program (6 weekly, 2-hour group workshops on nutrition education, family wellness, and physical activity)
Trial: 22688849
Drug: Peginterferon/ribavirin lead-in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon/ribavirin lead-in therapy
Trial: 19223704
Drug: Active surgical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active surgical treatment
Trial: 15902303
Drug: Mutated nonautoreactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mutated nonautoreactive CLL antibody sequences reverted to germline counterparts
Trial: 12581508
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium aerosol (4 mg) inhaled 30 minutes before allergen challenge
Trial: 9873197
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of GH
Trial: 9873197
Drug: Combined continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined continuous infusion and bolus injections of GH
Trial: 9873197
Drug: Bolus injections
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injections of GH
Trial: 9873197
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous (s.c.) infusion of GH
Trial: 9873197
Drug: Daily s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily s.c. injections of GH
Trial: 6356898
Drug: Labetalol 200
RxNorm normalized name: HCTZ 25/LABETALOL 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 200 mg (single dose and three times a day for three days)
Trial: 6356898
Drug: Labetalol 300
RxNorm normalized name: labetalol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 300 mg (single dose and twice a day for three days)
Trial: 6356898
Drug: Labetalol 200
RxNorm normalized name: HCTZ 25/LABETALOL 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 200 mg three times a day
Trial: 6356898
Drug: Labetalol 300
RxNorm normalized name: labetalol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 300 mg twice a day
Trial: 29608340
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (4 weekly 1-hour group-based exercise classes targeting strength training, endurance, balance, and flexibility)
Trial: 30205379
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg/day plus PTX (400 mg b.i.d.)
Trial: 30205379
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg/day plus placebo
Trial: 25823668
Drug: RG7652 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7652 400 mg every 4 weeks
Trial: 25823668
Drug: RG7652 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7652 800 mg every 8 weeks
Trial: 8669268
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg a day
Trial: 8669268
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg a day (combined with Cetirizine)
Trial: 9338613
Drug: Azelastine (Allergodil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine (Allergodil nasal spray)
Trial: 6395279
Drug: Multiple-dose cefoxitin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose cefoxitin
Trial: 6395279
Drug: Single-dose cefonicid
RxNorm normalized name: cefonicid
DrugBank: Cefonicid (DB01328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose cefonicid
Trial: 29577681
Drug: Radotinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radotinib (400 mg once daily)
Trial: 24475284
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no endotoxin administration)
Trial: 22776778
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg saxagliptin QD + COC QD for 21 days
Trial: 22776778
Drug: COC (Ortho-Cyclen)
RxNorm normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COC (Ortho-Cyclen) once daily for 21 days
Trial: 21135325
Drug: Maintenance antidepressant
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance antidepressant medication
Trial: 9861123
Drug: Morphine 0.3
RxNorm normalized name: ethylmorphine 0.32 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.3 mg kg-1 at induction of anaesthesia
Trial: 9861123
Drug: Placebo (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (morphine given 30 min later at skin incision)
Trial: 2664670
Drug: Intraoperative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative and postoperative cefuroxime (1500 mg and 750 mg intravenously, followed by 750 mg every eight hours for 24 hours postoperatively)
Trial: 2664670
Drug: Intraoperative cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative cefuroxime (1500 mg and 750 mg intravenously)
Trial: 1276626
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy followed by chemotherapy
Trial: 31170077
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of wrist robot-assisted training and tDCS
Trial: 28500815
Drug: Oral pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pentoxifylline plus pentavalent antimony (Sbv)
Trial: 20740685
Drug: Odanacatib (ODN)
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (ODN) 50 mg weekly
Trial: 2446060
Drug: Ketanserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20 mg) + Hydrochlorothiazide (25 mg)
Trial: 2446060
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg) + Hydrochlorothiazide (12.5 mg)
Trial: 27110370
Drug: Sitagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (50 mg, once daily)
Trial: 27110370
Drug: Voglibose (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose (0.6 mg, thrice daily)
Trial: 20633748
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon treatment (IFA) for 24 weeks
Trial: 18691996
Drug: Rosuvastatin vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin vs Pravastatin 20 mg
Trial: 12464950
Drug: Budesonide 0.8
RxNorm normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 0.8 mg/daily for 3 weeks
Trial: 12464950
Drug: Budesonide 0.8
RxNorm normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 0.8 mg/daily for 6 weeks
Trial: 12464950
Drug: Budesonide 0.8
RxNorm normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 0.8 mg/daily
Trial: 7573091
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 40 mg methylprednisolone acetate
Trial: 7573091
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 40 mg methylprednisolone acetate
Trial: 28369340
Drug: Vericiguat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat (10 mg)
Trial: 28369340
Drug: Vericiguat (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat (pooled three highest dose arms)
Trial: 25648342
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with injectable testosterone undecanoate (1,000 mg on day 1, additional injections at weeks 6 and 18) and daily tadalafil (5 mg) for 30 weeks
Trial: 25648342
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with injectable testosterone undecanoate (1,000 mg on day 1, additional injections at weeks 6 and 18) and on-demand tadalafil (10-20 mg) for 30 weeks
Trial: 25648342
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving the same testosterone treatment but with on-demand tadalafil (10-20 mg)
Trial: 25648342
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (daily tadalafil 5 mg)
Trial: 21198671
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated vaccines
Trial: 21198671
Drug: Inactivated vaccines
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated vaccines
Trial: 21198671
Drug: Inactivated vaccines
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated vaccines with oil-in-water emulsion adjuvants (e.g., MF59)
Trial: 21198671
Drug: Non-adjuvanted inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted inactivated vaccines
Trial: 12937039
Drug: Serum CMV
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CMV IgM antibodies
Trial: 11106042
Drug: Ceftriaxone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (50 mg/kg)
Trial: 3545882
Drug: Biostim 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biostim 2 mg/day
Trial: 3545882
Drug: Biostim 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biostim 8 mg/day
Trial: 31503274
Drug: Methotrexate (25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (25mg weekly)